| HOME >> BIOLOGY >> TECHNOLOGY |
Thursday, 12 March 2009
Poster 0074
Early Prognosis Prediction: MammaPrint on Core-needle biopsies
F. de Snoo, A. Glas, A. Floore, J. Mayordomo, A. Modollel, C. Rolfo, LJ
van 't Veer, E.
Thursday, 12 March 2009
Poster 0075
Use of the Genomic Test MammaPrint in Daily Clinical Practice to Assist in Risk Stratification of Young Breast Cancer Patients
G. Kunz, A. Glas and F. de Snoo, I. Simon.
About MammaPrint(R)
MammaPrint is the first 'in vitro diagnostic multivariate index assay' (IVDMIA) cleared by the U.S. Food and Drug Administration (FDA). FDA clearance requires clinical and analytical validation and reporting systems to ensure patient safety issues are addressed. Highly accurate, MammaPrint identifies patients with early metastasis-those patients who are likely to develop metastases within five years following surgery. Several authoritative studies have shown that chemotherapy particularly reduces early metastasis risk. In planning treatment, the MammaPrint test result provides a doctor with a clear rationale to assess the benefit of chemotherapy in addition to other clinical information and pathology tests.
All MammaPrint tests are conducted in Agendia's CLIA-accredited service laboratory. Breast cancer recurrence assays currently marketed by other manufacturers have not been subject to the rigorous FDA clearance process.
About Agendia
Agendia is at the forefront of the personalized medicine revolution,
striving to bring more effective, individualized treatments within reach of
patients. Building on a cutting edge genomics platform for tumor gene
expression profiling, the company's tests aim to help physician
'/>"/>
| SOURCE Agendia B.V. Copyright©2009 PR Newswire. All rights reserved |